Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.71 and traded as high as $2.33. Adaptimmune Therapeutics shares last traded at $2.32, with a volume of 515,641 shares.
Adaptimmune Therapeutics Stock Performance
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.03.
Get Adaptimmune Therapeutics alerts:Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06). The business had revenue of $3.58 million during the quarter, compared to analysts' expectations of $4.00 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative return on equity of 86.57%. During the same quarter in the previous year, the company earned ($0.24) EPS. Sell-side analysts forecast that Adaptimmune Therapeutics plc will post -1.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Inspire Investing LLC acquired a new stake in shares of Adaptimmune Therapeutics during the fourth quarter worth approximately $58,000. Daiwa Securities Group Inc. increased its holdings in shares of Adaptimmune Therapeutics by 59.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 24,515 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 13.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 69,140 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 8,292 shares in the last quarter. Syncona Portfolio Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $5,165,000. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $511,000.Adaptimmune Therapeutics Company Profile
(Get Rating)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Featured Stories
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.